<?xml version="1.0" encoding="UTF-8"?>
<p>At the 25th ICAR at Sapporo, Japan (2012), Mike gave an update on GS-7977 (formerly PSI-7977), including reporting the results of the ELECTRON trial.
 <sup>
  <xref rid="bibr6-2040206618783924" ref-type="bibr">6</xref>
 </sup> This must be one of only a few ICAR presentations which foretold such a great improvement in clinical therapy. In my 2016 ICAR meeting report,
 <sup>
  <xref rid="bibr7-2040206618783924" ref-type="bibr">7</xref>
 </sup> Jerome Deval (Alios BioPharma) and his colleagues chose to screen only nucleoside analogues for activity against RSV. Now, ALS-8176 (lumicitabine) looks set to become the game-changer for RSV therapy as sofosbuvir was for HCV therapy. Their success follows in the footsteps of Pharmasset. At this 2017 ICAR, the Zika vaccine (Pei-Yong Shi) may be another game-changing therapy â€“ I understand that, since ICAR, this vaccine has been selected for progression.
</p>
